We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

125 hedge funds and large institutions have $905M invested in C4 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $5.3M

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

5% more funds holding

Funds holding: 119 → 125 (+6)

2.76% more ownership

Funds ownership: 73.81% → 76.58% (+2.8%)

22% less capital invested

Capital invested by funds: $1.15B → $905M (-$249M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
125
Holders Change
+6
Holders Change %
+5.04%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
29
Increased
47
Reduced
32
Closed
23
Calls
$13.1M
Puts
$5.3M
Net Calls
+$7.83M
Net Calls Change
+$5.92M

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$49.5M
2
State Street
State Street
Massachusetts
+$15.5M
3
PVI
Pura Vida Investments
New York
+$14.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.1M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$44.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$32.1M
3
LCM
Laurion Capital Management
New York
-$18.7M
4
SCM
Soleus Capital Management
Connecticut
-$9.58M
5
Invesco
Invesco
Georgia
-$7.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$8M -$321K -13,220 -4%
PHS
27
PFM Health Sciences
California
$6.91M +$6.91M +284,772 New
Charles Schwab
28
Charles Schwab
California
$6.63M +$206K +8,486 +3%
EC
29
EcoR1 Capital
California
$4.85M – – –
SCM
30
Soleus Capital Management
Connecticut
$4.04M -$9.58M -394,386 -70%
AllianceBernstein
31
AllianceBernstein
Tennessee
$3.51M +$1.02M +42,154 +41%
Invesco
32
Invesco
Georgia
$3.36M -$7.91M -325,790 -70%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$3.29M +$1.05M +43,385 +47%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$3.18M +$152K +6,250 +5%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$3.08M +$38.9K +1,601 +1%
Mariner
36
Mariner
Kansas
$3.03M +$3.04M +125,030 New
Goldman Sachs
37
Goldman Sachs
New York
$2.91M -$2.55M -105,059 -47%
CPWM
38
Cypress Point Wealth Management
Texas
$2.88M +$2.88M +118,573 New
Two Sigma Investments
39
Two Sigma Investments
New York
$2.79M +$2.79M +114,931 New
Citadel Advisors
40
Citadel Advisors
Florida
$2.63M -$1.3M -53,727 -33%
TD Asset Management
41
TD Asset Management
Ontario, Canada
$2.6M +$19.4K +800 +0.8%
Bank of America
42
Bank of America
North Carolina
$2.52M +$51.1K +2,105 +2%
SSA
43
Schonfeld Strategic Advisors
New York
$2.17M +$1.08M +44,550 +99%
VIG
44
Vienna Insurance Group
Poland
$2.06M +$971K +40,000 +89%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.05M +$1.58M +65,224 +330%
JP Morgan Chase
46
JP Morgan Chase
New York
$1.68M +$988K +40,698 +142%
BG
47
Bellevue Group
Switzerland
$1.32M +$177K +7,300 +15%
Ohio Public Employees Retirement System (OPERS)
48
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.16M +$264K +10,863 +29%
EHI
49
Eagle Health Investments
Connecticut
$1.15M – – –
CAM
50
Cresset Asset Management
Illinois
$1.1M +$48.6K +2,000 +5%
1
2
3 4 5

CCCC Hedge Fund Activity: Q1 2022 in Review

125 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2022, worth a combined $905M — down 22% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CCCC positions and 23 closed out — a net gain of 6 holders — while 47 added to existing stakes and 32 trimmed.

The largest buyer was RTW Investments, adding an estimated $49.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $44.4M sold.

  • 125 institutional investors held C4 Therapeutics (CCCC) as of Q1 2022, up from 119 in Q4 2021.
  • Funds reported $905M of C4 Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
  • 29 funds opened new C4 Therapeutics positions in Q1 2022 and 23 closed out, a net change of +6 holders.
  • The largest C4 Therapeutics buyer in Q1 2022 was RTW Investments, an estimated $49.5M added.
  • The largest C4 Therapeutics seller in Q1 2022 was RA Capital Management, an estimated $44.4M sold.

Based on aggregated 13F filings for Q1 2022.